Solteq had lowered its guidance ahead of the earnings report and the net sales decline of 6.
SRV's net sales in Q3 amounted to EUR 183.5m, slightly above our estimate of EUR 179.
Vitrolife continues to improve its organic growth, and the company has delivered two quarters with c...
Redeye retains its positive view of Fortnox following a solid Q3 report that meets our expectations.
Redeye leaves an initial comment following the Q3 report published by Magle this morning.
Sales and ARR in line with ABGSCe Limited consensus estimate revisions are likely Strong margin due ...
Fiskars’ Q3 adjusted EBIT of EUR 24.3m came 1% above LSEG Data & Analytics consensus expectations.
Redeye notes that Gasporox's report came in below Redeye Estimates (RRe) across the board while prod...
Redeye comments on Sleep Cycle's Q3 2024 report, which showed a growth rate of 8.
Redeye sees that the Q3 financials were not too far from our estimates (though we were slightly too ...
Redeye comments on Polygiene Group´s third quarter of the year.
Redeye provides its initial take on ADDvise’s Q3 2024 report, which came in broadly below our estima...
XVIVO delivers a Q3 that aligns with our expectations but is below market expectations due to FX hea...
Redeye comments on Evolution’s Q3-results which was close to our estimates and the company looks to ...
Redeye comments on SHH´s third quarter of the year.
Redeye’s first take on the Q3 report this morning. There were considerable changes in sales in the d...
Sales -1% y-o-y, -3% vs. ABGSCe EBIT of SEK 63m, 75% vs.
Redeye will likely increase its forecasts and Base Case following a solid Q3 report from Addnode.
Redeye initiates coverage of Neola Medical, a Swedish medtech company specialising in neonatal inten...
Redeye continues to see a compelling long-term investment case.